Global Ranibizumab Market Research Report 2023-Competitive Analysis, Status and Outlook by Type, Downstream Industry, and Geography, Forecast to 2029

Global Ranibizumab Market Research Report 2023-Competitive Analysis, Status and Outlook by Type, Downstream Industry, and Geography, Forecast to 2029

Ranibizumab is a monoclonal antibody fragment obtained from bevacizumab from the same parental murine antibody. It is much smaller than the parent molecule and binds more tightly to vascular endothelial growth factor-A. It is an angiogenesis inhibitor that has been approved for the treatment of wet age-related macular degeneration.

Market Overview:

The latest research study on the global Ranibizumab market finds that the global Ranibizumab market reached a value of USD 2730.92 million in 2022. It’s expected that the market will achieve USD 3406.85 million by 2028, exhibiting a CAGR of 3.75% during the forecast period.

Strength

Development of economy and technology.
The product has obvious efficacy and excellent quality.
The increase in the number of people with eye diseases has brought a lot of demand.

Weakness

High R&D expenses in the early stage and high technical content.
Regional development is uneven, many regions are underdeveloped, and the market is narrow.

Opportunity

Exchanges and cooperation between suppliers deepen.
Growing opportunities in emerging markets, such as China, Japan.

Threat

The impact of trade war.
Government control will be more strict.

Threat

from alternatives.

Region Overview:

North America is projected to account for a considerable share of the Ranibizumab market and is expected to become the largest region by 2028.

Company Overview:

Novartis is one of the major players operating in the Ranibizumab market, holding a share of 55.71% in 2021.

Novartis

Novartis is a pharmaceutical and biotechnology multinational company headquartered in Basel, Switzerland. Its core business is in the fields of patents, consumer health, generics, eye care and animal health. Novartis was founded in 1996 by the merger of two chemical and pharmaceutical companies in Basel, Ciba-Geigy and Sandoz.

Genentech

Genentech is a scientifically innovative research-oriented company with more than 1,100 researchers, scientists, and post-graduate students who conduct a wide range of scientific research and development – from molecular biology to protein chemistry to bioinformatics and physiology. Scientists in different fields of Genentech now target five disease categories: oncology, immunology, tissue growth and repair, neuroscience and infectious diseases.

Segmentation Overview:

As for product types, the Single-use Glass Vial segment held the largest market share in 2022.

Application Overview:

By application, the wAMD segment occupied the biggest share from 2018 to 2022.

wAMD

wAMD is characterized by sudden loss of monocular vision, distortion of the subject or central dark spots, and the other eye may appear symptoms after a longer period of time. Subretinal hemorrhage and exudation in the posterior pole of the fundus, sometimes with gray-yellow lesions, which may be neovascularization.

Diabetic Retinopathy (DR)

Diabetic retinopathy is the result of chronic progressive retinal microvascular leakage and obstruction caused by diabetes. To some extent, all diabetic patients will eventually have this change.

Diabetic Macular Edema (DME)

Diabetic macular edema (DME) refers to retinal thickening or hard exudation deposition caused by the accumulation of extracellular fluid in the foveal diameter of the macula due to diabetes.

mCNV

Myopic choroidal neovascularization refers to proliferating blood vessels from the choroidal capillaries that extend through the rupture of the Bruch membrane, between the Bruch membrane and the retinal pigment epithelium, or between the neural retina and the retinal pigment epithelium, or between the retinal pigment epithelium and the choroid. Proliferation, many diseases involving the RPE-Bruch membrane-choroidal capillary complex can lead to the formation of CNV, also known as subretinal neovascularization.

RVO

Retinal vein occlusion is a common fundus vascular disease. Retinal vein occlusion (RVO) is a common high-blind retinal vascular disease that affects the main complication of vision in patients with macular edema (ME).

Key Companies in the global Ranibizumab market covered in Chapter 3:

Genentech
Novartis

In Chapter 4 and Chapter 14.2, on the basis of types, the Ranibizumab market from 2018 to 2029 is primarily split into:

Single-use Prefilled Syringe
Single-use Glass Vial

In Chapter 5 and Chapter 14.3, on the basis of Downstream Industry, the Ranibizumab market from 2018 to 2029 covers:

wAMD
Diabetic Retinopathy (DR)
Diabetic Macular Edema (DME)
mCNV
RVO

Geographically, the detailed analysis of consumption, revenue, market share and growth rate, historic and forecast (2018-2029) of the following regions are covered in Chapter 8 to Chapter 14:

North America (United States, Canada)
Europe (Germany, UK, France, Italy, Spain, Russia, Netherlands, Turkey, Switzerland, Sweden)
Asia Pacific (China, Japan, South Korea, Australia, India, Indonesia, Philippines, Malaysia)
Latin America (Brazil, Mexico, Argentina)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa)